"The Mechanic" Cellular Energy Optimization Protocol

Your body makes energy the same way it always has. But somewhere in your 30s and 40s, the machinery starts losing efficiency, and most people assume that is just aging. It is not just aging. It is a specific set of failures happening in a specific sequence, and once you understand the sequence, the protocol makes sense.

Here is the full chain before anything else. Your mitochondria take food and oxygen and convert them into ATP, which is the actual currency your cells spend on every function they perform. That conversion happens along something called the electron transport chain, which is a series of protein complexes embedded in the inner mitochondrial membrane. Electrons move through those complexes like current through a wire, and as they move, they pump protons across the membrane, and that proton gradient drives the production of ATP. The whole thing depends on the membrane being intact, the complexes being functional, and a steady supply of raw materials feeding into the system. When any of those three things fail, your energy production drops.

What changes with age is all three.

The membrane problem comes first and it is structural. The inner mitochondrial membrane is held in its folded shape by something called cardiolipin, which is a specialized phospholipid that anchors the protein complexes in the correct geometry and keeps electrons moving efficiently through the chain. When cardiolipin gets oxidized and damaged, the folds flatten, the complexes drift apart, and electrons start leaking out of the chain before they complete the transfer. Those leaked electrons react with oxygen to produce something called reactive oxygen species, which are unstable molecules that damage nearby structures including, critically, more cardiolipin. So the damage feeds itself.

The second failure is NAD+ depletion, and this one has a mechanism most people have not heard of. NAD+ is the molecule your mitochondria use to carry electrons into the transport chain. Without it, the chain has nothing to move. What causes the depletion as you age is not primarily a production problem. It is a consumption problem driven by an enzyme called CD38, which breaks down NAD+ as part of an immune response. Research published in Cell Metabolism found that CD38 activity increases two to three fold with aging, and mice bred without CD38 maintained their NAD+ levels at every age that was tested. The enzyme is not a small factor. It is a primary driver.

What makes the CD38 story more complete is a second paper published in Nature Metabolism showing that senescent cells are the ones triggering the CD38 increase. Senescent cells are cells that have stopped dividing but refuse to die, and they secrete a cocktail of inflammatory signals called the SASP. Those signals recruit macrophages and cause them to upregulate CD38. So the chain goes: senescent cells accumulate, they inflame the tissue, that inflammation cranks up CD38, CD38 consumes your NAD+, and your electron transport chain runs dry. The senescent cells are not a separate problem from the NAD+ problem. They are the upstream cause of it.

That is why the protocol runs in a specific order.

The foundation phase covers the inputs the system needs regardless of condition. Creatine at five grams per day supports ATP regeneration directly through the phosphocreatine system, which recycles ATP faster than oxidative phosphorylation can during peak demand. CoQ10 covers the electron shuttle function because CoQ10 is the actual carrier molecule that moves electrons from complex one and complex two to complex three in the transport chain, and that molecule declines meaningfully with age. Without enough of it, the chain stalls even if everything else is intact.

The repair phase addresses the structural damage. SS-31 is a peptide that concentrates specifically on the inner mitochondrial membrane and binds to cardiolipin, stabilizing it against oxidation. Research in the Journal of the American Society of Nephrology showed that SS-31 stabilizes the folded cristae structure and reduces electron leakage, which means less ROS production and more efficient ATP output. The conservative dosing in the protocol, one to two milligrams per day for four to eight weeks, reflects the current state of human data, which is limited but consistent with the mechanism.

FOXO4-DRI addresses the senescent cell burden directly. Senescent cells survive by exploiting a survival signal that involves a protein called FOXO4 holding another protein called p53 inside the cell so it cannot trigger apoptosis, which is the cell's built-in death program. FOXO4-DRI is a modified peptide that disrupts that interaction, freeing p53 to do its job. The Cell paper from 2017 measured 11.73-fold selectivity for senescent cells over healthy cells, meaning healthy cells are largely unaffected at therapeutic doses. The transient immune response people notice during this phase, feeling off for a few days, is the immune system clearing the apoptotic debris. That is the process working, not a side effect to suppress.

Epithalon is added for telomere support. Research on human fibroblasts showed that Epithalon induced expression of hTERT, which is the catalytic component of telomerase, and produced measurable telomere elongation. It runs for 10 to 20 days, one to two times per year, which is a low-frequency intervention relative to how long its effects appear to persist based on animal data.

The optimization phase introduces MOTS-c, a peptide that is produced naturally in mitochondria and functions as a metabolic regulator. It activates something called AMPK, which is an energy-sensing enzyme that shifts cells into an efficiency mode when it detects low energy availability. The Lee et al. paper in Cell Metabolism showed that MOTS-c prevents diet-induced insulin resistance and promotes metabolic homeostasis in animal models, specifically through inhibition of the folate cycle which feeds into AMPK activation. The sequencing matters here: you activate MOTS-c after the membrane has been stabilized by SS-31, because pushing a damaged mitochondria to perform harder through AMPK activation before repairing the cardiolipin problem would be like flooring the accelerator in a car with a cracked engine block.

On NAD+ specifically, two papers have now confirmed that most oral NMN and NR is converted to niacin pathway metabolites in the gut before absorption, meaning the gut is completing the same conversion pathway that plain niacin enters directly. Niacin at pennies per dose reaches the same downstream outcome. If injectable NAD+ is already in your stack and you feel it is working, the mechanism supports continuing it, but the oral supplement premium is not supported by the absorption data.

L-carnitine deserves mention because its mechanism is singular. It is the only molecule that can transport long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation. If your mitochondria are repaired and optimized and your carnitine is depleted, the cell cannot access fat as fuel. Injectable delivery at 200 to 500 milligrams bypasses the absorption ceiling that limits oral carnitine.

The deeper principle running through all of this is that energy decline is a layered structural problem, not a single deficiency. Most people treat it as one thing, reach for one supplement, and wonder why it does not move the needle. The membrane fails first, the senescent cells drive the NAD+ problem second, and the metabolic efficiency problem follows both of those. Fix them in order or you are patching the wrong layer.

---

References

1. Birk AV, Liu S, Soong Y, et al. The Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting with Cardiolipin. Journal of the American Society of Nephrology. 2013;248:1250-1261. Finding: SS-31 selectively binds cardiolipin on the inner mitochondrial membrane, stabilizing cristae structure. Source
2. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology. 2014;1718:2029-2050. Finding: SS-31 binds cardiolipin, stabilizes mitochondrial membrane structure, and reduces electron leakage and ROS production. Source
3. Baar MP, Brandt RMC, Putavet DA, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;1691:132-147. Finding: FOXO4-DRI disrupts FOXO4-p53 interaction in senescent cells, freeing p53 to trigger apoptosis. 11.73-fold selectivity for senescent vs healthy cells. Source
4. Camacho-Pereira J, Tarrago MG, Chini CCS, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metabolism. 2016;236:1127-1139. Finding: CD38 activity increases 2-3 fold with age. CD38 knockout mice maintained NAD+ levels at all ages. Source
5. Covarrubias AJ, Kale A, Perrone R, et al. Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages. Nature Metabolism. 2020;211:1265-1283. Finding: Senescent cell SASP cytokines induce macrophages to upregulate CD38, establishing the causal chain from senescence to NAD+ decline. Source
6. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;1356:590-592. Finding: Epithalon induced hTERT expression, telomerase activity, and telomere elongation in human fibroblasts. Source
7. Goncharova ND, Vengerin AA, Khavinson VKh, Lapin BA. Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas. Experimental Gerontology. 2005;401-2:51-57. Finding: Epithalamin at 5mg/day and synthetic Epithalon at 10mcg/day achieved equivalent melatonin restoration in aged monkeys, demonstrating 500-fold potency difference. Source
8. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;213:443-454. Finding: MOTS-c activates AMPK via inhibition of the folate cycle. Prevented insulin resistance and diet-induced obesity. Source
9. Shats I, Williams JG, Liu J, et al. Bacteria Boost Mammalian Host NAD Metabolism by Engaging the Deamidated Biosynthesis Pathway. Cell Metabolism. 2020;313:564-579. Finding: Gut bacteria deamidate nicotinamide to nicotinic acid niacin, confirming NMN/NR undergo gut conversion before absorption. Source
10. Kim LJ, et al. Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD+ synthesis via enterohepatic circulation. Science Advances. 2025. Finding: Most oral NMN and NR is converted to niacin-pathway metabolites in the gut before absorption. Source
11. Costford SR, Bajpeyi S, Pasarica M, et al. Skeletal muscle NAMPT is induced by exercise in humans. American Journal of Physiology - Endocrinology and Metabolism. 2010;2981:E117-E126. Finding: NAMPT protein increased 127% in sedentary subjects after exercise training. Source
12. Longo N, Frigeni M, Pasquali M. Carnitine transport and fatty acid oxidation. Biochimica et Biophysica Acta. 2016;186310:2422-2435. Finding: L-carnitine is the sole molecule carrying long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation. Source
13. Banerjee R, Purhonen J, Bhardwaj R, Bhargava A, Kallijarvi J. The mitochondrial coenzyme Q junction and complex III. The FEBS Journal. 2022;28922:6936-6958. Finding: CoQ serves as the mobile electron carrier between Complex I/II and Complex III. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness